Sorrento Therapeutics, Inc.
SRNE · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$108,437 | -$154,626 | -$227,114 | -$90,626 |
| Dep. & Amort. | $3,593 | $3,623 | $3,353 | $3,358 |
| Deferred Tax | -$11,847 | $11,494 | -$1,154 | -$11 |
| Stock-Based Comp. | $15,194 | $18,282 | $17,230 | $18,501 |
| Change in WC | $33,450 | $30,642 | $43,565 | $24,907 |
| Other Non-Cash | $12,388 | $11,130 | $95,782 | -$17,300 |
| Operating Cash Flow | -$55,659 | -$49,459 | -$68,338 | -$61,171 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$140 | -$86 | -$4,524 | -$3,835 |
| Net Acquisitions | $0 | $0 | -$510 | -$4,257 |
| Inv. Purchases | $0 | $0 | $0 | -$4,257 |
| Inv. Sales/Matur. | $0 | $1,770 | $0 | $0 |
| Other Inv. Act. | $0 | $1,770 | $0 | $0 |
| Investing Cash Flow | -$140 | $1,684 | -$5,034 | -$8,092 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $85,070 | $38,225 | -$38,017 | $23 |
| Stock Issued | -$2,185 | $22,971 | $62,298 | $71,455 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$11 | -$14,282 | $0 | $0 |
| Other Fin. Act. | $5,939 | $14,282 | $799 | $20 |
| Financing Cash Flow | $88,813 | $61,196 | $25,080 | $71,498 |
| Forex Effect | -$920 | $600 | $1,240 | -$1,894 |
| Net Chg. in Cash | $32,094 | $14,021 | -$47,052 | $341 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $37,655 | $23,634 | $70,686 | $70,345 |
| End Cash | $69,749 | $37,655 | $23,634 | $70,686 |
| Free Cash Flow | -$55,799 | -$49,545 | -$72,862 | -$65,006 |